Longevity Science Foundation

06/23/2026

We're pleased to welcome LongeVC as the official longevity sponsor of the Invested in Her campaign, focused on women's health, menopause, and ovarian aging.

LongeVC is a venture capital firm investing in breakthrough biotechnology and supporting early-stage founders working to bring scientific advances from research into real-world application. Through its portfolio and global network of scientists, entrepreneurs, and industry leaders, the firm helps accelerate the development of new approaches across medicine and biotechnology. LongeVC has supported the Longevity Science Foundation since its inception, and as part of its commitment to the Invested in Her campaign, has pledged a $25,000 matching contribution that will be unlocked if and once the fundraising goal is reached.

As an investor in early-stage science, LongeVC is closely engaged with areas where fundamental questions in medicine remain unresolved.

Addressing disparities in women’s health is both a scientific and ethical imperative. We're grateful to have LongeVC join this effort. Learn more about their work here: https://longevc.com

Women shouldn’t have to wait decades longer for their health to be properly understood and addressed. It’s time to get fully Invested in Her.

06/18/2026

We're pleased to welcome Revitalization Unlimited as the official historic real estate sponsor of the Invested in Her campaign, focused on women's health, menopause, and ovarian aging.

Revitalization Unlimited helps accredited investors access tax-efficient real estate opportunities by preserving historic commercial buildings that most funds overlook. The firm combines tax-efficient historic real estate as its anchor strategy with manufacturing acquisitions as a return enhancer, seeking to generate long-term value for investors while preserving important pieces of America's economic and architectural heritage.

The firm's focus on identifying overlooked opportunities resonates with the goals of Invested in Her. Women's health, menopause, and ovarian aging have received far less scientific attention and funding than their impact warrants, despite their profound influence on health, wellbeing, and quality of life across populations. Bringing greater scientific focus and investment to these areas is a necessary step toward strengthening the foundations of women's healthcare.

Addressing these disparities is both a scientific and ethical imperative. We're grateful to have Revitalization Unlimited join this effort. Learn more about their work here: https://revitalizationunlimited.com

Women shouldn’t have to wait decades longer for their health to be properly understood and addressed. It’s time to get fully Invested in Her.

06/17/2026

We're grateful to see the Invested in Her campaign featured by Longevity.Technology. Beyond fundraising, this initiative is about building momentum around questions that affect hundreds of millions of women worldwide. Every conversation, introduction, and contribution helps move the field forward and supports the researchers working to generate answers.

Thank you to Eleanor Garth, Phil Newman, and the Longevity.Technology team for helping bring visibility to our work. Read the full article here: https://longevity.technology/news/can-crowdfunding-change-ovarian-aging-research-and-opinions/

New Longevity Science Foundation campaign aims to raise funds – and public pressure – for overlooked driver of female healthspan.

Link as first comment.

06/12/2026

We're pleased to welcome Tactical Tax & Estate Planning (Tactical Tax Strategies) as the official tax strategy sponsor of the Invested in Her campaign, focused on Women's Health, Menopause, and Ovarian Aging.

Tactical Tax Strategies is a Scottsdale-based financial services firm specializing in tax mitigation, tax-efficient income, estate and retirement planning strategies, for more effective wealth transfer solutions. The firm works closely with financial advisors, attorneys, CPAs and their clients to translate complex financial structures into actionable planning.

Their decision to join the initiative reflects a shared recognition that this is not only a scientific gap but also an ethical one. Women's health has historically been underfunded and underprioritized, despite its direct impact on quality of life, family systems, and long-term healthspan outcomes. For Tactical Tax Strategies, this aligns with a simple but important idea: meaningful planning for the future must also account for how that future is lived, not just how it is financed.

Closing this gap is both a scientific and practical imperative. We're grateful to have Tactical Tax Strategies join this effort. Learn more about their work here: https://steptax.com/

Women shouldn’t have to wait decades longer for their health to be properly understood and addressed. It’s time to get fully Invested in Her.

06/10/2026

We’re pleased to welcome Clear Inc. as the official water sponsor of the Invested in Her campaign, supporting our efforts and funding research on women’s health, menopause, and ovarian aging.

Clear, a water purification systems company born from a personal encounter with waterborne illness, is redefining water quality in real estate. By installing, monitoring, and servicing trusted purification technology, Clear helps ensure that the water flowing through the buildings they serve is clean, safe, and healthy for thousands of families worldwide. Founded after its CEO experienced firsthand the consequences of unsafe water, the company approaches water quality as a foundational health issue rather than a simple building utility. Through centralized UV purification, real-time monitoring, and ongoing servicing, their prevention-first model extends beyond conventional water testing by focusing on microbial risks before they become a problem, demonstrating an approach to health that prioritizes prevention and long-term wellbeing.

Clear’s support reflects a belief that women’s health deserves greater scientific attention, investment, and urgency than it has historically received. Despite affecting billions of lives worldwide, research into female biology, ovarian aging, and menopause has long received less funding and focus than its impact warrants.

Clear, we are grateful for your support of research in women’s health, and your commitment to invest where it matters most. Together, we can generate insights that improve quality and length of life, reduce disease burden, and benefit generations of women to come.

We’re grateful to have Clear join this effort. Learn more about their work here: https://clear.inc/

Women shouldn’t have to wait decades longer for their health to be properly understood and addressed. It’s time to get fully Invested in Her.

06/03/2026

Hundreds of millions of women live longer than men, yet spend significantly more years in poor health. The gender gap between lifespan and healthspan is partly rooted in a longstanding imbalance in medical research. For much of modern medical history, the male body served as the default model for research and clinical practice. Women were frequently excluded from studies, underrepresented in clinical trials, and insufficiently reflected in the datasets used to shape diagnosis, treatment, and standards of care. The effects of that imbalance continue to influence health outcomes today.

Our mission is to make longevity accessible to everyone. As part of this effort, we support with the potential to improve global health within a meaningful timeframe. One example is our Female Fertility & Longevity grant call, which focuses on ovarian , hormonal health, and interventions that address one of the most consequential biological transitions in a woman's life – menopause. By supporting research in this area, we aim to advance a deeper understanding of the mechanisms that shape women's health across the lifespan.

Over the past months, we have published a series of evidence-based articles exploring key aspects of women's health, including:

▶️ Why midlife represents a major biological transition and how it affects the brain, cardiovascular system, bones, metabolism, mood, and pelvic health.

▶️ Hormone replacement therapy (HRT) explained in practical terms: who may benefit, when it may be appropriate, and what conversations to have with a menopause-informed clinician.

▶️ How cardiovascular disease and can manifest differently in women.

▶️ Practical guidance for women in their 40s and 50s – which questions to ask and where to begin.

▶️ Nutrition and exercise strategies that support mass, metabolic health, bone strength, and long-term independence.

▶️ What the evidence actually says about women's sleep, including the importance of consistency, sleep quality, and recovery.

The article below brings these topics together in a single resource. Rather than offering another collection of health tips, it provides a practical overview of what changes during this stage of life, which interventions are supported by evidence, and where important scientific uncertainties still remain. We also discuss how emerging research, including work supported by the LSF, may help close some of these knowledge gaps in the years ahead. If you've been looking for a comprehensive, evidence-based introduction to women's health, , and healthy aging, this is a good place to start.

Read the "Women's Health, In One Place" article here: https://longevity.foundation/tpost/c3xf0bipf1-womens-health-in-one-place

05/29/2026

Anthropic and the Gates Foundation have announced a four-year, $200 million partnership focused on deploying AI across global health, life sciences, education, and agriculture. The initiative combines grant funding, Claude usage credits, technical support, and the development of public datasets, benchmarks, and more.

A major component of the partnership centers on healthcare and biomedical research. According to both organizations, Anthropic’s Claude models will be applied to areas including vaccine development, disease surveillance, and the identification of potential therapeutic candidates for under-researched diseases such as polio, HPV, and preeclampsia. The collaboration will also include healthcare intelligence systems and evaluation frameworks designed to help researchers, governments, and public health organizations work with complex medical datasets more effectively.

This reflects a broader expansion of AI into healthcare-adjacent domains such as drug discovery and biomedical research, alongside novel applications in clinical and diagnostic settings. While many of these efforts are in their early stages, the broader trajectory is becoming increasingly difficult to ignore.

The implications for longevity and age-related disease research may also prove significant. Many biological processes associated with aging, (e.g., chronic inflammation, immune dysfunction, neurodegeneration) involve highly complex systems that generate enormous volumes of fragmented biological and clinical data. AI systems capable of assisting with pattern detection, hypothesis generation, target prioritization, and analysis can meaningfully accelerate parts of the research pipeline, particularly in places where conventional approaches remain slow and resource-intensive.

The LSF continues to monitor developments at the intersection of AI, biotechnology, and longevity science as these fields increasingly shape the future of healthcare and age-related disease research. We invite you to learn more about our work and funding focus: https://longevity.foundation/support-us

05/20/2026

The image below, sourced from Stifel's BioPharma Market Update (January 2026) (originally highlighted by on X), charts some of the most consequential biomedical innovations of the past decade.

From the approval of Kymriah for blood cancers in 2017 to Journavx for acute pain in 2025, the concentration of novel treatment modalities in a single decade has been remarkable by any historical measure. Each milestone represents years of scientific persistence and, behind it, a capital commitment made long before anyone knew whether the bet would pay off.

This critical piece largely remains unacknowledged: the drugs approved today were seeded by research often conducted 15 to 20 years ago, and sometimes longer. The pipeline that produces future breakthroughs is being built right now, in university labs and preclinical programs that generate no commercial revenue and offer no near-term ROI. This is where conventional financing sources, such as venture capital and private equity, are structurally limited. Without a clear market pathway, private capital cannot reach the science on which progress hinges.

What has historically filled that gap is public funding. When it diminishes, the gap does not close on its own. This is how drug development works: basic science receives backing, insights accumulate over years, a company eventually forms around a validated target, private capital arrives, and a decade or so later, a treatment reaches patients. If the first step is removed, the entire sequence stalls.

Nonprofit grant-making organizations like the LSF occupy a distinct position in this ecosystem. Unconstrained by return timelines or portfolio concentration risk, they can fund science that is too early, too speculative, or too neglected to attract commercial interest.

We operate in this niche because innovation demands it. The LSF channels philanthropic capital into high-impact early-stage research across geroscience, age-related disease, and underrepresented populations – the upstream science that will anchor the next generation of breakthroughs. The image below is an argument both for optimism about scientific achievement, and the urgency of our cause. If you believe in the case for early-stage, promising science and the role of philanthropic capital in sustaining it, we invite you to support our work: https://longevity.foundation/support-us

05/14/2026

What happens to cognition when AI does the heavy lifting?

A recent study published in Social Sciences & Humanities Open examined whether unrestricted access to ChatGPT during self-directed study helps or harms long-term knowledge retention. The trial, framed around the concept of ChatGPT as a cognitive crutch, offers one of the first experimental data points on a question that has largely been left to speculation.

The findings appear striking: students who used ChatGPT as a study aid scored significantly lower on a surprise retention test administered 45 days after learning (57.5%) than those who relied on traditional methods (68.5%). The AI-assisted group also spent substantially less time on the task, suggesting that access to ChatGPT reduced the effortful engagement that supports durable memory formation. These results fit into a broader and increasingly difficult-to-ignore pattern: as AI becomes a default resource for hundreds of millions of people worldwide, the cumulative effect on how we learn, remember, and process information is quietly compounding. The convenience of outsourcing cognitive work to a chatbot may come at a cost that does not always surface immediately.

None of this diminishes what AI is capable of: across healthcare, scientific research, financial services, and beyond, these tools are accelerating progress in ways that were unimaginable a decade ago. However, the question we should consider is where the line should be drawn. Offloading routine tasks is reasonable, but delegating ideation, information synthesis, and decision-making may present certain health risks. There is a meaningful difference between using AI to challenge assumptions and using it to replace the thinking we should be doing ourselves.

While the findings are thought-provoking and deserve attention, it is important to be mindful that this is a single study with a modest sample and conducted in a specific context. Replication across broader populations and varied AI use cases is needed before treating these results as definitive. What is clear, however, is that we need to be increasingly vigilant in our use of AI, and its impact on brain health at the individual level, within organizations, and across society. This conversation warrants ongoing attention. Learn more about the intersection of AI and cognition from our CEO's panel participation at the Future Proof Citywide conference here:

https://longevity.foundation/news/tpost/oem135ipg1-event-recap-the-lsf-at-the-future-proof

05/06/2026

Physical activity is one of the most consistently supported interventions linked to a lower biological age.

A recent systematic review and meta-analysis published in The Lancet Healthy Longevity examined how exercise relates to biological aging using DNA methylation clocks, widely used research tools that estimate biological age based on molecular patterns associated with aging.

The study reviewed 44 human studies, covering more than 145,000 participants across a wide age range. By aggregating data from multiple cohorts, the researchers assessed whether higher levels of physical activity were associated with differences in epigenetic age acceleration. The results suggest an overall pattern: individuals with higher physical activity levels tended to show lower biological age signals, particularly when measured using the Horvath and GrimAge clocks. In simple terms, more active individuals appeared biologically younger, although effect sizes were relatively modest and not all measures showed consistent associations. We are also pleased to see our Scientific Advisory Board member, Prof. Andrea B. Maier, among the contributing authors of this work.

Most of the available evidence comes from cross-sectional studies, limiting conclusions about causality. More longitudinal research will be needed to determine how exactly exercise influences aging trajectories over time. Still, the direction of the findings is broadly consistent with decades of research linking physical activity to improved health outcomes and reduced risk of age-related disease.

The takeaway is fairly straightforward: if the goal is to support healthy longevity, the starting point remains the fundamentals. Physical activity is not a marginal intervention or an emerging trend, but one of the most well-established and accessible ways to improve long-term health. We invite you to read the LSF’s articles covering the intersection of longevity, muscle, and physical activity: https://longevity.foundation/education #!/tfeeds/570878103061/c/Exercise%20&%20Muscle